RESEARCH PAPER
Reporting rates for cervical screening in the Szczecin Region during the period 2007–2010
More details
Hide details
1
Higher School of Public Health, Zielona Góra, Poland
2
Department of Health Education, University of Szczecin, Szczecin, Poland
3
Medical University, Łódź, Poland
4
Department for Health Problems of Ageing, Institute of Rural Health in Lublin, Poland
Ann Agric Environ Med. 2012;19(4):686-691
KEYWORDS
ABSTRACT
In Poland, the incidence of cervical cancer remains on the level of the mean value observed in the regions of Eastern and Central Europe; however, it is higher than in Western Europe. The effects of performance of prophylactic programmes would be more effective if an improvement was observed in the reporting by women for examinations, and the quality and accessibility of these tests was observed, in accordance with international standards. The objective of the study was analysis of the reporting rates for cervical screening in the Szczecin Region during the period 2007-2010.
Statistical data were analyzed obtained from: the Central (Poznań) and Regional (Szczecin, Olsztyn) Coordination Centre for the Programme of Prophylaxis and Early Detection of Cervical Cancer of the Medical Prophylaxis Computer Information System (SIMP), and Oncology Centre in Warsaw. All collected data were subjected to the statistical analyses.
The West Pomeranian Voivodeship, with reporting rates for cervical test of about 30% (women aged 25-59) occupies the second or third position in Poland, following the Varmian-Masurian Voivodeship. Personal invitations and screening examinations, as well as an increase in the number of services providers at the basic level in the West Pomeranian Voivodeship, have not been sufficiently effective in ways of increasing reporting rates for cervical tests. Apart from personal invitations, the patients acquired knowledge concerning screening from many sources, primarily from medical specialists, nurses and the media.
The obtaining of further reduction in mortality and morbidity in the West Pomeranian Voivodeship requires the development of new methods which would result in an increase in the number of women participating in cervical screening, to cover with examinations a minimum of 70-75% of the population.
REFERENCES (24)
1.
Parkin D. The global health burden of infection-associated cancer in the year 2002. Int J Cancer. 2006; 118: 3030-3044.
2.
Ferlay J, Bray P, Pizani P, Parkin DM. GLOBOCAN 2008: Cancer incidence, mortality and prevalence worldwide. IARC Cancer Base No 5, Version 2 0 IARCPress, Lyon.
3.
Didkowska J, Wojciechowska U, Zatoński W. Nowotwory szyjki macicy w Polsce – epidemiologiczny bilans otwarcia i perspektywy Ginekol Pol. 2006; 77: 660-666.
4.
Krajowy Rejestr Nowotworów. Centrum Onkologii – Instytut im. Marii Skłodowskiej-Curie. Zakład Epidemiologii i Prewencji Nowotworów, htp://epid.coi.waw.pl/krn/ (access: 23.01.2011).
5.
Chosia M, Domagała W. West-Pomeranian program of cervical cancer prevention. Results of phase one study. J Oncol. 2003; 53: 409-413.
6.
Program wykrywania raka szyjki macicy nagrodzony. “Pearl of Wisdom” Europejskie Stowarzyszenie Raka Szyjki Macicy (ECCA).
http://www.pulsmedycyny.compl/...: 25.01.2010).
7.
Spaczyńskim M. Polskie Towarzystwo Ginekologiczne. Rekomendacje PTG dotyczące diagnostyki, profilaktyki i wczesnego wykrywania raka szyjki macicy. Ginekol Pol. 2006; 77: 655-659.
8.
Spaczyński M, Nowak-Markwitz E, Basta A. Rekomendacje PTG dotyczące szczepienia przeciwko zakażeniom HPV. Ginekol Pol. 2007; 78: 185-190.
9.
Rezolucja Parlamentu Europejskiego z 10.04.2008; w sprawie zwalczania nowotworów w rozszerzonej Europie. Punkt V.2.
10.
Wronkowski Z, Zwierko M, Nowacki MP, Raport z Programu modelowego skryningu raka piersi i raka szyjki macicy w Polsce, 1999-2000; COI Warszawa 2002.
11.
Zatoński W. (ed.) Europejski Kodeks Walki z Rakiem, Cetrum Onkologii, Warszawa 2003.
12.
Kancelaria Senatu Unii Europejskiej. Sprawozdanie 6/8 Bruksela, 9 kwietnia 2008; g. 20.00.
13.
Olszewski WT. Badania przesiewowe w kierunku nowotworów. In: Krzakowski M. (ed.) Onkologia Kliniczna. Borgis, Warszawa 2006.
14.
Eaker S, Adami H, Sparen P. Reasons women do not attend screening for cervical cancer: a population – based study in Sweden. Prev Med. 2001; 32: 482-491.
15.
International Agency for Research on Cancer (IARC) Working Group on the Evaluation of Cervical Cancer Screening Programmes. Screening for squamous cervical cancer: duration of low risk after negative results of cervical cytology and its implication for screening policies. Brit Med J. 1986; 293(6548): 659-664.
16.
Sasieni PD, Cuzick J, Lynch-Farmery E. Estimating the efficacy of screening by auditing smear histories of women with and without cervical cancer. The National Coordinating Network for Cervical Screening Working Group. Brit J Cancer. 1996; 73(8): 1001-1005.
17.
Sigurdsson K. Trends in cervical intra-epithelial neoplasia in Iceland through 1995: evaluation of targeted age groups and screening intervals. Acta Obstet Gynecol Scand. 1999; 78: 486-492.
18.
Saslow D, Runowicz C, Solomon D. American Cancer Society guideline for the early detection of cervical neoplasia and cancer. CA Cancer J Clin. 2002; 52: 342-362.
19.
Spaczyński M, Nowak-Markwitz E, Kędzia W, Januszek-Michalecka L, Michalska M. Skryning w Polsce na tle państw Unii Europejskiej. In: Spaczyński M, Kędzia W, Nowak-Markwitz E. (eds.) Rak Szyjki Macicy. Profilaktyka, diagnostyka leczenie. PZWL, Warszawa 2009.
20.
Karsa L, Antilla A, Ronco G. Cancer Screening in the European Union. Report on the implementation of the Council Recommendation on cancer screening. First report. IARC, 2008.
21.
Council Recommendation of 2 December 2003 on cancer screening, Oficial Journal of the EuropeanUnion,16.12.2003http://eur-lex.europa.eu/LexUriServ/LexUriServ. OJ:L:2003: 327:0034: 0038:EN (access: 20.04.2011).
22.
Arbyn M, Antilla A, Jordan J, et al. European guidelines for quality assurance in cervical cancer screening. Second edition. IARC, 2008.
23.
Didkowska J, Wojciechowska U, Zatoński W. Nowotwory szyjki macicy w Polsce — epidemiologiczny bilans otwarcia i perspektywy Ginekol Pol. 2006; 77: 660-666.
24.
Fałek A. Informacja Ministerstwa Zdrowia na temat leczenia chorób onkologicznych, Warszawa, 5.01.2011.